| 前收盘价格 | 1.97 |
| 收盘价格 | 2.03 |
| 成交量 | 168,453 |
| 平均成交量 (3个月) | 834,887 |
| 市值 | 3,600,000 |
| 价格/销量 (P/S) | 20.23 |
| 股市价格/股市净资产 (P/B) | 7.65 |
| 52周波幅 | |
| 利润日期 | 29 May 2025 - 2 Jun 2025 |
| 营业利益率 (TTM) | -14,450.00% |
| 稀释每股收益 (EPS TTM) | -10.08 |
| 季度收入增长率 (YOY) | 380.00% |
| 总债务/股东权益 (D/E MRQ) | 291.21% |
| 流动比率 (MRQ) | 0.710 |
| 营业现金流 (OCF TTM) | -10.10 M |
| 杠杆自由现金流 (LFCF TTM) | -5.72 M |
| 资产报酬率 (ROA TTM) | -123.36% |
| 股东权益报酬率 (ROE TTM) | -378.40% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | VivoSim Labs, Inc. | - | - |
AIStockmoo 评分
-0.9
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -4.0 |
| 平均 | -0.88 |
|
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 1.53% |
| 机构持股比例 | 12.21% |
| 日期 | 类型 | 细节 |
|---|---|---|
| 23 Apr 2025 | 公告 | VivoSim to Carry Forward Organovo 3D Bioprinting |
| 02 Apr 2025 | 公告 | Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements |
| 27 Mar 2025 | 公告 | Organovo Provides Business Update |
| 25 Mar 2025 | 公告 | Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company |
| 19 Mar 2025 | 公告 | Organovo Announces Reverse Stock Split |
| 06 Mar 2025 | 公告 | Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises |
| 25 Feb 2025 | 公告 | Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合